Literature DB >> 9540985

Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts.

L Mattila1, K Airola, M Ahonen, M Hietarinta, C Black, U Saarialho-Kere, V M Kähäri.   

Abstract

Excessive accumulation of fibrillar collagens is a hallmark of the cutaneous fibrosis in both systemic and localized scleroderma. Turnover of the collagenous extracellular matrix is dependent on the balance between collagenolytic matrix metalloproteinases and their specific inhibitors. We have examined the expression of the novel, matrix associated tissue inhibitor of metalloproteinases-3 (TIMP-3) in normal and scleroderma skin fibroblasts in culture and in vivo. The levels of TIMP-3 mRNA were elevated up to 2.5-fold in five of seven systemic sclerosis fibroblast strains, whereas TIMP-1 mRNA expression was elevated up to 1.8-fold in two and TIMP-2 mRNA expression up to 1.8-fold in two systemic sclerosis strains. Using in situ hybridization, TIMP-3 mRNA was detected in seven of 12 localized scleroderma skin samples, specifically in fibroblasts within fibrotic collagen fibers or in the vicinity of inflammatory cells. TIMP-1 mRNA was detected in three of eight scleroderma skin samples in fibroblasts adjacent to inflammatory cells. The expression of TIMP-3 mRNA by systemic sclerosis and normal skin fibroblasts was enhanced to a similar extent (by 8.6- and 8.1-fold, respectively) by transforming growth factor-beta, and suppressed down to 34 and 54%, respectively, by tumor necrosis factor-alpha. Specific activation of TIMP-3 gene expression in scleroderma skin fibroblasts in culture and in vivo suggests a role for TIMP-3 in the pathogenesis of dermal fibrosis via inhibition of turnover of fibrotic dermal extracellular matrix, possibly due to upregulation of TIMP-3 expression by transforming growth factor-beta.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9540985     DOI: 10.1046/j.1523-1747.1998.00138.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  16 in total

Review 1.  The promise of transcription profiling for understanding the pathogenesis of scleroderma.

Authors:  D R Strehlow
Journal:  Curr Rheumatol Rep       Date:  2000-12       Impact factor: 4.592

Review 2.  Matrix metalloproteinase biology applied to vitreoretinal disorders.

Authors:  C S Sethi; T A Bailey; P J Luthert; N H Chong
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

3.  Serum levels of soluble CD21 in patients with systemic sclerosis.

Authors:  Manabu Tomita; Takafumi Kadono; Norihito Yazawa; Tomohiko Kawashima; Zenshiro Tamaki; Ryuichi Ashida; Hanako Ohmatsu; Yoshihide Asano; Makoto Sugaya; Masahide Kubo; Hironobu Ihn; Kunihiko Tamaki; Shinichi Sato
Journal:  Rheumatol Int       Date:  2010-10-30       Impact factor: 2.631

Review 4.  Scleroderma, fibroblasts, signaling, and excessive extracellular matrix.

Authors:  Hironobu Ihn
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

5.  Persistence of TGF-beta1 induction of increased fibroblast contractility.

Authors:  X D Liu; T Umino; R Ertl; T Veys; C M Skold; K Takigawa; D J Romberger; J R Spurzem; Y K Zhu; T Kohyama; H Wang; S I Rennard
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-03       Impact factor: 2.416

6.  Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.

Authors:  S A Young-Min; C Beeton; R Laughton; T Plumpton; S Bartram; G Murphy; C Black; T E Cawston
Journal:  Ann Rheum Dis       Date:  2001-09       Impact factor: 19.103

7.  Tissue inhibitors of metalloproteinase-expressing cells in human anterior pituitary and pituitary adenoma.

Authors:  Alimuddin Tofrizal; Ken Fujiwara; Morio Azuma; Motoshi Kikuchi; Depicha Jindatip; Takashi Yashiro; Shozo Yamada
Journal:  Med Mol Morphol       Date:  2017-03-28       Impact factor: 2.309

8.  Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis.

Authors:  C Nishijima; I Hayakawa; T Matsushita; K Komura; M Hasegawa; K Takehara; S Sato
Journal:  Clin Exp Immunol       Date:  2004-11       Impact factor: 4.330

9.  Increased levels of serum tissue inhibitor of metalloproteinase-1 but not metalloproteinase-3 in atopic dermatitis.

Authors:  N Katoh; S Hirano; M Suehiro; K Ikenaga; H Yasuno
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

10.  A Case of Minocycline-induced Linear Morphea Reactivation.

Authors:  Cory Pettit; Joy Mosser-Goldfarb
Journal:  J Clin Aesthet Dermatol       Date:  2021-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.